Services
TissUse offers high-value service contracts to create custom solutions for safety evaluation of drugs, cosmetics and chemicals, and pre-clinical human disease modelling. Any new chip design serving customer needs with a specific organ arrangement can be prototyped and produced at short notice due to a proprietary rapid prototyping procedure established at TissUse.
The versatile TissUse approach addresses multiple organs & tissues to make the right chip for the right assay.
Drug development
Our goal is to deliver the tools to accelerate drug development through these stages together with all the scientists over the world towards patient’s benefit. Our experienced team with long-standing expertise in Multi-Organ-Chip assay development (>50 MOC publications) will design your flexible, efficient and reliable assay for safety or efficacy testing.
- Safety: Identify hazards before moving on to exposing organisms with your substance of interest.
- Efficacy: Get early and strong indication of your substance performance early in the development process.
Examples of established assays by TissUse
DMPK / Safety / Hazard identification
Mode of Action / Efficacy
| No. | Organ model | Schematic | Context of use | Level of readiness | Species |
| 1 | Blood-Brain-barrier – Neuro – Liver |  |
BBB permeability, organ toxicity, metabolite neurotoxicity | III | Human |
| 2 | Bone marrow |  |
Bone marrow toxicity, chemotherapy scheduling, erythropoiesis | III | Human |
| 3 | Hair follicle |  |
Hair growth agents | III | Human |
| 4 | Intestine – Liver |  |
Absorption, metabolism | III | Human |
| 5 | Intestine – Liver – Kidney – Neuro |  |
ADME-profiling, PBPK, first-path metabolism, primary & secondary organ toxicity | III | Human |
| 6 | Intestine – Liver – Kidney – Neuro + Blood-Brain-Barrier |  |
ADME-profiling, PBPK, first-path metabolism, primary & secondary organ toxicity | III | Human |
| 7 | Lung – Liver |  |
Hazard identification | III | Human |
| 8 | Pancreas – Liver |  |
Diabetes target finding, mathematical modeling | III | Human |
| 9 | Skin – Liver |  |
Compound PK/PD, skin irritancy, toxicity, first-path metabolism | III | Human |
| 10 | Skin – Tumor |  |
Anti-tumor antibodies | III | Human |
| 11 | Thyroid – Liver |  |
Endocrine disruption | III | Human vs. Rat |
| 12 | Liver |  |
Drug evaluation | II | Human |
| 13 | Lung |  |
Nanoparticle toxicity | II | Human |
| 14 | Skin – Liver – Thyroid |  |
Repeated dose topical and systemic administration | II | Human |
| 15 | Testis – Liver |  |
Testicular toxicity | II | Human |
| 16 | Vasculature – Pancreas – Tumor |  |
Anti-tumor therapy | II | Human |
| 17 | Bone |  |
Nanoparticle toxicity | I | Human |
| 18 | Cardio – Liver |  |
Metabolite cardiotoxicity | I | Human |
| 19 | Endometrium |  |
Physiology/Pathology | I | Human |
| 20 | Intestine – Skeletal muscle |  |
Muscle growth agents | I | Human vs. Pig |
| 21 | Kidney (glomerulus) – Liver |  |
Therapeutic effect of MSC-derived extracellular vesicles | I | Human |
| 22 | Kidney (proximal tubules) – Liver | |
Repeated dose proximal tubules toxicity | I | Human |
| 23 | Neuro – Liver |  |
Metabolite neurotoxicity | I | Human |
| 24 | Immunocompetent Skin – Gingiva |  |
Skin and oral toxicity | I | Human |
| 25 | Skin including dermal papillae |  |
Skin sensitizer | I* | Human |
| 26 | Skin – Leukocytes |  |
Allograft rejection therapies | I | Human |
| 27 | Tumor (DLBCL) – Liver |  |
Personalized automatized cancer treatment | I | Human |
III Assay established, available for testing/assay transfer
II Model established, available for assay development
I Proof of Concept, available for joint development or *independently developed by partner lab